Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending August 2013. The report details a specific share repurchase transaction executed on August 14, 2013, authorized by shareholders at the Annual General Meeting on May 1, 2013.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margins, debt, or liquidity figures. It focuses exclusively on share capital and treasury holdings.
- Shares Purchased: 445,000 Ordinary Shares of 25 pence each.
- Price Range: Highest price paid was 1,701.50 pence per share; lowest was 1,682.00 pence per share.
- Treasury Holdings (Settled): 508,740,412 shares (9.40% of total issued share capital).
- Treasury Holdings (Including Unsettled): 509,905,412 shares (10.40% of total voting rights).
- Shares in Issue (Excluding Treasury): 4,904,091,196 shares.
Material Changes
The primary material change is the increase in treasury shares following the purchase of 445,000 shares. The filing does not provide comparative data for prior periods regarding financial performance or share counts.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It is a compliance disclosure confirming conformity with the Financial Conduct Authority's Disclosure and Transparency Rules.
Investor Verification Checklist
- Verify the total number of shares held in Treasury (508,740,412 settled) against the company's latest annual report.
- Confirm the total issued share capital to validate the 9.40% treasury ownership calculation.
- Check the settlement status of the 445,000 shares purchased on August 14, 2013, to reconcile the difference between settled and unsettled treasury holdings.
- Review the Financial Conduct Authority's Disclosure and Transparency Rules to understand notification thresholds based on the 4,904,091,196 shares in issue.